NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
Clinical Trials
7 trialsNCT01332279 2023-04-04
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
Fox Chase Cancer Center
Phase 1 Withdrawn
NCT00428194 2017-11-29
Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Withdrawn
NCT00934076 2015-05-08
Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT01432119 2013-04-09
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00738335 2012-10-04
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
University of California, San Francisco
Phase 1 Withdrawn
NCT00754104 2011-01-19
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
Abbott
Phase 1 Withdrawn